Deep Breeze™: Novel Software Application Extends VRI(TM) Capabilities to Predicting Post-Operative Lung Function  
3/18/2009 11:03:31 AM

MANNHEIM, Germany--(BUSINESS WIRE)--Deep Breeze Ltd., manufacturer of the FDA approved VRIxp™ & VRIxv™ lung imaging systems, announced that it has received CE mark for its O-Plan application extending the usefulness of Deep Breeze's revolutionary VRI™ technology to patients eligible for lung cancer resection. The application has recently received the CE mark and it is used by thoracic surgeons in European Union countries.